Substituted Prolines as Orexin Receptor Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for malconditions related to orexin receptor dysfunction, such as eating disorders, obesity, and addiction, lack effective modulators that can specifically target and modulate orexin receptors OX1 and OX2 to provide therapeutic benefits.
Innovation Solution
Development of non-peptidic small molecules that can activate or inhibit orexin receptors OX1 or OX2, represented by a compound of formula (I), which includes aryl or heteroaryl groups with specific substitutions, allowing for modulation of orexin receptor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-peptidic small molecules are developed to target orexin receptors, then therapeutic benefits for eating disorders, obesity, and addiction are achieved, but the lack of effective modulators previously limited treatment options
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters including substituent groups (J, R′, R1, Ra, Rb, R2), ring structures (A, B, D), and stereochemistry to optimize orexin receptor binding affinity and selectivity. This enables the development of effective small molecule modulators where none previously existed, resolving the contradiction between therapeutic effectiveness and availability of modulators.
Solution Approach 2:
The patent employs local quality by introducing specific substituent groups at particular positions on the core molecular structure. Different substituents (halo, oxo, hydroxy, cyano, alkyl, alkoxy, acyloxy, acylamido, and their variations) are placed at specific locations to fine-tune receptor interaction properties, enabling effective modulation while maintaining structural diversity.
2Measurement precision
If specific substituent groups and ring structures are incorporated into the molecular structure, then orexin receptor selectivity is improved, but molecular complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional modules: a core structure (formula I) with defined substituent positions (J, R′, R1, Ra, Rb, R2) and variable ring systems (A, B, D). This modular approach enables systematic optimization of receptor selectivity while managing molecular complexity through structured variation of discrete elements.
Solution Approach 2:
The patent employs universality by designing a core molecular framework (formula I) that can accommodate multiple types of substituents and ring systems, allowing a single base structure to generate multiple receptor-selective compounds. This multi-functional design enables the same core structure to target orexin receptors with different selectivity profiles based on substituent variations.
Data Source
AI summary
The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease.